Ken Griffin Nektar Therapeutics Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.11 - $1.48 $12,099 - $16,132	10,900 Added 573.68%	12,800 $16,000
Q2 2024 Aug 14, 2024	SELL	$0.9 - $1.83 $14,760 - $30,012	-16,400 Reduced 89.62%	1,900 $2,000
Q1 2024 May 15, 2024	BUY	$0.49 - $0.96 $4,018 - $7,872	8,200 Added 81.19%	18,300 $17,000
Q4 2023 Feb 14, 2024	BUY	$0.42 - $0.57 $840 - $1,140	2,000 Added 24.69%	10,100 $5,000
Q3 2023 Nov 14, 2023	SELL	$0.51 - $1.05 $9,180 - $18,900	-18,000 Reduced 68.97%	8,100 $4,000
Q2 2023 Aug 14, 2023	SELL	$0.53 - $1.03 $34,556 - $67,156	-65,200 Reduced 71.41%	26,100 $15,000
Q1 2023 May 15, 2023	BUY	$0.64 - $3.15 $51,584 - $253,890	80,600 Added 753.27%	91,300 $63,000
Q4 2022 Feb 14, 2023	SELL	$2.03 - $4.28 $71,456 - $150,656	-35,200 Reduced 76.69%	10,700 $24,000
Q3 2022 Nov 14, 2022	SELL	$3.04 - $5.14 $100,928 - $170,648	-33,200 Reduced 41.97%	45,900 $147,000

147

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $240M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.